glp-1 news november 3 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1 Agonists Market Report 2025-2033,

Lastly, most trials (and observational studies) did not consider duration of diabetes as an eligibility criterion or account for this by subgroup analyses

[13] [23] Post-marketing surveillance and patient reports have documented cases of hair thinning or increased hair shedding amongst individuals taking GLP-1 medications, particularly those experiencing substantial weight loss

Nevertheless, liver function tests are still recommended and vildagliptin is not approved for use in patients with hepatic insufficiency

Therapies with faster or no titration could improve patient and provider experience

From the very beginning, the onboarding process impressed me

Nausea, vomiting, diarrhea and constipation are common especially as the body is adjusting to higher doses of the drug